Affordable prescription drugs are necessary so individuals can benefit from advances in medicine to treat conditions such as familial hypercholesterolemia. Medical research and innovation make it possible to actually prevent or delay heart disease in people born with FH. All it takes is early diagnosis … Read More
Author Archives: Cat Davis Ahmed
Ask the Pharmacy – Are you getting the lowest cost for your PCSK9 inhibitor?
The manufacturers of both PCSK9 inhibitors, Praluent and Repatha, have lowered the list price for these cholesterol-lowering treatments by 60% to $5,850 per year. As we reported in February, the FH Foundation continues … Read More
The FH Foundation welcomes Sanofi and Regeneron’s announcement today to lower the list price of its LDL cholesterol lowering treatment, the PCSK9 inhibitor Praluent, to $5,850 annually. This brings the list price of Praluent in line with Amgen’s PCSK9 inhibitor, Repatha, which was lowered … Read More
The FH Foundation went to Capitol Hill on January 28-29 to raise awareness of Familial Hypercholesterolemia among our nation’s elected officials, and advocate for Federal funding for FH research.
Our 2019 class of 25 new volunteer FH Advocates for Awareness held 36 meetings with Congressional Offices … Read More
What does it mean for FH?
The American College of Cardiology and the American Heart Association published a new guideline for the management of cholesterol in November 2018. The guideline was developed by a distinguished group of experts and endorsed by 10 other respected professional organizations. … Read More
This week I heard about a young family who lost their husband and father, suddenly and right in front of their eyes. He had a massive heart attack and was gone. Sadly, working for the FH Foundation, I have heard this story too many times. It’s especially heartbreaking because we know that when heart … Read More